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Abstract: Astrocytic tumours are associated with dismal prognoses due to their pronounced ability to diffusely 
invade the brain parenchyma. Various neuropeptides, including gastrin, are able to modulate tumour astrocyte 
migration. While neurotensin has been shown to influence the proliferation of glioma cells and the migratory 
ability of a large set of other cell types, its role in glioma cell migration has never been investigated. 
Neurotensin-induced modifications to the motility features of human U373 glioblastoma cells therefore 
constitute the topic of the present study. We evidenced that three subtypes of neurotensin receptors (NTR1, 
NTR2 and NTR3) are expressed in U373 glioblastoma cells, at least as far as their mRNAs are concerned. 
Treating U373 tumour cells with 10 nM neurotensin markedly modified the morphological patterns of these cells 
and also profoundly altered the organization of their actin cytoskeletons. Pull-down assays revealed that 
neurotensin induced the activation in U373 cells of both Racl and Cdc42 but not RhoA. Scratch wound assays 
evidenced that neurotensin (0.1 and 10 nM) very significantly inhibited wound colonization by U373 cells 
cultured in the absence of serum. In addition, quantitative phase-contrast videomicroscopy analyses showed that 
neurotensin decreases the motility levels of U373 glioblastoma cells when these cells are cultured on plastic. In 
sharp contrast, neurotensin stimulates the motility of U373 cells when they are cultured on laminin, which is a 
pro-adhesive extracellular matrix component ubiquitously secreted by glioma cells. Our data thus strongly 
suggest that, in addition to gastrin, neurotensin is a neuropeptide capable of modulating tumour astrocyte 
migration into the brain parenchyma. 
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Introduction 
The World Health Organization (WHO) classifies astrocytic tumours into four histopathological grades 
according to their levels of malignancy [1]. Grade I includes benign tumours like pilocytic astrocytomas and 
subependymal giant cell astrocytomas, Grade II tumours are associated with a rather good prognosis of 10-20 
years' survival after the initial diagnosis while Grades III (anaplastic astrocytomas) and IV (glioblastomas) are 
highly malignant tumours associated with dismal prognoses [2]. Indeed, about 90% of glioblastoma patients die 
in the year following the initial diagnosis of their tumours. The malignant nature of astrocytic tumours is directly 
related to their ability to diffusely invade the brain parenchyma, so making complete surgical resections 
impossible [2]. Various neuropeptides (for example, angiotensin, bombesin, bradykinin, cholecystokinin, 
endothelin, gastrin and neurotensin, etc.) are able to modify the biological behaviour of tumour astrocytes [3]. 
We accordingly show that chole-cystokinin/gastrin-related peptides modify both the cell proliferation [4,5] and 
the migratory [6-8] characteristics of glioblastoma cells. Astrocytic tumours also express neurotensin receptors 
(NTRs) [9], and we have previously shown that neurotensin is able to significantly modify the proliferation rates 
of various human astrocytic tumour cell lines [10]. 
The invasive abilities of individual tumour astrocytes mainly depend on their migratory potential, which is 
related to three processes, that is, their adhesion to extracellular matrix (ECM) components and other cells, their 
motility involving the dynamics of the cell cytoskeleton, and their invasive ability that requires the degradation 
of matrix proteins by proteolytic enzymes. To migrate, glioma cells secrete ECM components that facilitate their 
motility [11-13]. Laminin - a pro-adhesive ECM component - is ubiquitously secreted by glioma cells 
[11,12,14]; it is upregulated in human high-grade diffuse astrocytic tumours [12,14] and strongly stimulates 
glioma cell motility in vitro [15]. The major steps involved in cell movement are the extension of a leading edge 
protrusion or lamellipodium, the establishment of new adhesion sites at the leading edge, the contraction of the 
cell body and the release of the adhesion at the rear [16]. All these steps involve the assembly, the disassembly 
or reorganization of the actin cytoskeleton. Most neuropeptides, including neurotensin, function biologically 
through binding to specific G-protein-coupled receptors (GPCRs) on the surface of the target cells [17], and this 
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binding to GPCRs in turn induces profound modifications in the organization of the actin cytoskeleton [18]. 
Small GTPases of the Rho family (that is, the Rho-GTPases), including RhoA, Cdc42 and Rac1, play a pivotal 
role in regulating the signalling pathways which are activated by the binding of neuropeptides to GPCRs [18] 
and which are relevant to cell migration [16]. These GTPases act as molecular switches to control the signal 
transduction pathways by cycling between a GDP-bound inactive form and a GTP-bound active one [16]. In 
their GTP-bound state, they interact with downstream targets (effectors) to elicit a variety of intracellular 
responses, including the reorganization of the actin cytoskeleton. While RhoA regulates the assembly of 
contractile acto-myosin filaments, Racl and Cdc42 regulate the polymerization of actin to form peripheral 
lamellipodial and filopodial protrusions respectively [19]. In addition, these three GTPases promote the assembly 
of integrin-based matrix adhesion complexes [20-22]. 
The aim of the present work is to characterize the effects of neurotensin on the motility characteristics of the U3 
73 model, an aggressive human glioma of astrocytic origins [23-25]. Neurotensin is widely distributed in the 
central nervous system (CNS) and its peripheral tissue, and its actions are mediated by specific receptors. Of the 
three subtypes of NTRs cloned, NTR1 and NTR2 belong to the family of GPCRs while NTR3 is a new type of 
neuropeptide receptor in the form of a 95-kDa protein (identical to gp95/sortilin) with a single transmembrane 
domain [9,26-28]. Different studies of rat CNS have revealed a widespread expression of these NTRs throughout 
the adult brain [29-31]. We made use of anRT-PCR approach to characterize at mRNA level the type of NTR 
present in U373 glioblastoma cells. In addition, we investigated the influence of neurotensin on the levels of 
activity of RhoA, Cdc42 and Racl, and on the organization of the actin cytoskeleton. Finally, we made use of 
two distinct cell migration assays to characterize the influence of neurotensin on the motility features of U373 
cells cultured on plastic and laminin. 
Materials and methods 
Cell culture 
The human glioma cell line U373, whose unique astrocytic origin we had previously confirmed [23,24], was 
obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA; HTB14). The cells were 
maintained as monolayers in a specific medium, as detailed elsewhere [4,24]. 
Compounds 
Neurotensin and laminin (from the basement membrane of Engelbreth-Holm-Swarm murine sarcoma) were 
purchased from Sigma (St Louis, MO, USA). Culture dishes were coated with laminin by allowing a stock 
solution (0.833 ng/ml) to dry on the surface for one night at room temperature. The dishes were rinsed twice with 
sterile phosphate-buffered saline (PBS, GibcoBRL, InvitrogenSA, Merelbeke, Belgium) just before the plating 
of the cells. 
Analysis of NTRs mRNA expression 
The U373 tumour cells were grown to subconfluence in plastic Falcon dishes, and total RNA was prepared with 
the High Pure RNA Isolation Kit (Roche Diagnostics, Vilvoorde, Belgium) according to the manufacturer's 
recommendations. The quantities of RNA extracted were measured with the Ribogreen Kit (Molecular Probes, 
Eugene, OR, USA). A second quantification was carried out by means of a spectrophotometer (at 260 and 280 
nm), which also enabled the sample quality to be checked (by means of the 260/280 ratio). Ten nanograms of 
total RNA were reverse-transcribed and amplified using the GeneAmp Thermostable rTth Reverse Transcriptase 
RNA PCR Kit (Perkin-Elmer, Boston, MA, USA) and specific pairs of primers (InvitrogenSA). The sequence of 
the primers, the numbers of PCR cycles and the size of the RT-PCR products are described in Table 1. These 
products were analysed on 10% polyacrylamide gels. After staining with GelStar dye (FMC BioProducts, 
Rockland, ME, USA) the signals were quantified using Fluor-S Multilmager (Bio-Rad, Hercules, CA, USA). 
The amplification of the 28S rRNA was carried out to check each RNA sample analysed (data not shown). The 
analysis of the mRNA expression or each NTR included a negative control (that is, water) which evidenced no 
band (data not shown). 
Pull-down assays 
Active GTP-bound forms of the three Rho GTPases were measured on U373 cells cultured on plastic as 
described by Ren et al. [32] and Sander et al. [33]. Cells were chilled on ice and lysed in an ice-cold buffer (50 
mM Tris pH 7.2 containing 1% Triton X-100, 150 mM NaCl, 10 mM MgCl2, 10 µg/ml each of leupeptin and 
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aprotinin, and 0.1 mM PMSF). The cell lysates were clarified by centrifugation at 13 000 g at 4°C for 8 min. 
Aliquots of the supernatants were denatured in SDS-PAGE lysis buffer (v/v) in order to measure the total 
amount of the Rho GTPases by Western blotting. For the pull-down assays the supernatants were incubated at 
4°C for 30 min with 30 µg of a fusion protein between glutathione-S-transferase (GST) and either the PBD 
domain of the Rac1- and Cdc42-effector PAK, or the RBD domain of the RhoA-effector Rhotekin, linked to 
glutathione-Sepharose beads (Amersham Biosciences, Buckinghamshire, UK). The beads were washed four 
times in lysis buffer and denaturated in SDS-PAGE buffer. The total and activated proteins were analysed in 
parallel by Western blotting with mouse monoclonal antibodies against RhoA, Racl or Cdc42. The anti-RhoA 
antibody (1/400) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), the anti-Racl (1/1000) 
from Upstate Biotechnology (Lake Placid, NY, USA), and the anti-Cdc42 (1/250) from Transduction 
Laboratories (San Diego, CA, USA). 
Analysis of the actin cytoskeleton 
Fluorescent phallacidin conjugated with Alexa Fluor® 488 fluorochrome (Molecular Probes Inc., Eugene, OR, 
USA) was used to label the fibrillar actin, and Alexa Fluor® 594-conjugated DNAseI (Molecular Probes Inc.) to 
stain the globular actin. The cells were cultured 48 h on glass coverslips prior to the fluorescence staining, as 
described elsewhere [8]. 
Cell motility measurements by means of computer-assisted videomicroscopy 
We developed and implemented a specialized software package on computers connected to phase-contrast 
videomicroscopy systems placed in 3 7°C-heated incubators [6,34]. This package enables the trajectories of 
individual cells to be established and quantitatively analysed (Figure 1 A,B)· The cell-tracking algorithm is based 
on a model-based approach using an adapted mean-shift process which enables each cell to be tracked efficiently 
for hours and which is able to produce detailed descriptions of individual cell trajectories [34]. We validated this 
software on several cell culture experiments by means of comparisons with human-controlled analyses [34]. The 
images were acquired and stored as previously described [6], Briefly, they were obtained under a phase-contrast 
microscope (Olympus, Aartselaan, Belgium; model 1X50, with a 10:1 magnification ratio) with a CCD video 
camera (Hitachi Denshi, Tokyo, Japan; model KP-M1E/K-S10) coupled to an acquisition board (32-bits Matrix 
Vision PC-GRAB-GI frame grabber). Image acquisition was effected every 4 min over a number of hours 
(typically 24 h, that is, 360 images). The dimensions of the images were 700 × 500 pixels discretized into 256 
grey levels (8 bits per pixel). The parameter used to characterize each cell trajectory was the Maximum Relative 
Distance from the point of Origin (MRDO). This refers to the greatest linear distance between the original 
position of a cell (at time = 0) and the farthest position reached by the cell in its trajectory (Figure 1C). The 
MRDO is this maximum distance normalized by the observation time for the cell analysed (to be able to 
compare cell trajectories corresponding to different observation times). The neurotensin effects were evaluated in 
terms of the MRDO variable on particular and complete cell populations. This is illustrated in Figure 1D, which 
shows how to identify a subpopulation of cells consisting of the 25% most motile ones (see the hatched vertical 
line) on the basis of the distribution of the MRDO values (the black bars). 
Table 1: Primers used to evidence the mRNA expression of NTRs 
 Oligonucleotide sequence (5 ' to 3 ') Number of cycles Size of PCR products 
NTR1 sense GCTTAAGAAGGTCGCCTAAGCCTA 40 423 bp 
NTR1 antisense GTTTGGCAGGAAGTGCAGCGAATA   
NTR2 sense CACTACTTCTACATGGTGACCAACA 40 474 bp 
NTR2 antisense CTAAGCACTTTAGTCTCAGGCAACA   
NTR3 sense CGTGTGTCAGAATGGTCGAGACTA 40 539 bp 
NTR3 antisense GGTCCTCATCTGAGTCATCATGATA   
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Figure 1: Cell motility tracking by means of computer-assisted videomicroscopy Starting from the initial cell 
positions indicated by the user (A), the method is able to reconstitute individual cell trajectories over dozens of hours (B). The level 
of individual cell motility is measured by means of the MRDO (Maximum Relative Distance from the point of Origin) variable, which is the 
maximum distance covered by a cell (red line in panel C) normalized by the observation time for this cell. Panel D illustrates both the 
distribution (in percentage) of the MRDO values computed on a cell population and the identification of the subpopulation consisting of the 
25% most motile cells (characterized by the 25% highest MRDO values, see the vertical hatched line). 
 
Scratch wound assay 
The U3 73 glioblastoma cells were grown to confluence in six well dishes. Scratch wounds were made by 
creating a linear decellularized region using a pipette tip (as illustrated in the Results). The cells were washed 
twice with PBS before their incubation in culture medium with neurotensin (0.1, 10 and 1000 nM). The 
colonization of the wound by the TJ3 73 cells cultured in a serum-free medium or in a medium supplemented 
with 5% foetal bovine serum and in the presence or the absence (control) of neurotensin was analysed for 40 h 
(at different points of time). Six fields of each of the three wounds analysed per condition were photographed 0, 
15, 24 and 40 h after the neurotensin treatment. An algorithm developed in our laboratory was used on the basis 
of these digital frames to quantify the area progressively filled by the cells over the period of the experiment. 
Statistical analysis 
Because the conditions for applying the parametric tests were not satisfied, we used nonparametric tests to 
compare independent groups of numerical data. Statistical comparisons between the multiple groups of cells 
were made by first carrying out the Kruskal-Wallis test (a non-parametric one-way analysis of variance). In cases 
where this test revealed significant differences, we investigated by means of the Mann-Whitney test whether any 
of the groups of treated cells differed from control. 
Results 
NTR1, NTR2 and NTR3 mRNAs are expressed in human U373 glioblastoma cells 
Figure 2 shows that the mRNAs for the three receptors identified to date for neurotensin are present in human 
U373 glioblastoma cells, that is, NTR1 (lane B), NTR2 (lane C) and NTR3 (lane D). In contrast, we did not 
evidence any secretion of neurotensin by these cells (by means of an Elisa assay, data not shown). 
Neurotensin activates small GTPases in human U373 glioblastoma cells cultured on plastic and modifies their 
morphology and actin cytoskeleton organization 
Figure 3A,B show morphological illustrations of U373 tumour cells cultured on plastic in the absence or the 
presence of 10 nM neurotensin. These illustrations show that neurotensin induced morphological responses by 
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increasing the number of filopodial protrusions ending in adhesion plaques in the treated cells (see the arrow in 
Figure 3B). As illustrated in Figure 3C,D, the staining of the fibrillar and globular actin revealed that the 
neurotensin increased the overall amount of fibrillary (green fluorescent) actin and induced its accumulation at 
the tips of the protrusions (see arrows in Figure 3D). The activity of the Rho GTPases, RhoA, Rac1 and Cdc42, 
was measured by means of pull-down assays. The U3 73 cells were either treated with 10 nM neurotensin for 5 
or 10 min, or left untreated (control). The cells treated for 5 min with the culture medium supplemented with 
serum (5%) were taken as positive control for Rac1 activation [35]. Figure 3E shows that while neurotensin did 
not activate RhoA, it did activate Racl and Cdc42 in a time-dependent manner in the U373 tumour cells. The 
total levels of the Rho GTPases were not altered by the neurotensin treatment. These neurotensin-induced effects 
on the GTPases activity can at least partly explain the morphological and the cytoskeletal changes seen in the 
neurotensin-treated U373 tumour cells. 
Figure 2: mRNA expression of the neurotensin receptors in U373 cells. Lane A shows the DNA ladder, lane B 
the NTR1 PCR product (423 bp), lane C the NTR2 PCR product (474 bp), lane D the NTR3 PCR product (its size 
should be at 539 bp but appears at more than 500 bp). 
 
Figure 3: Neurotensin-mediated effects on cell morphology and cytoskeleton and Rho-GTPase activation. Panels 
A and B illustrate the morphological aspects observed under phase-contrast microscopy of the D373 cells (cultured on plastic) left untreated 
or treated with neurotensin (10-8 M) respectively. The treated cells exhibited an increased number of filopodial protrusions ending in 
adhesion plaques (see the arrow in panel B). Panels C and D illustrate the modifications to the actin cytoskeleton (F-actin labelled in green 
and G-actin in red) observed in the D373 cells treated with neurotensin (10-8 M, D) as compared with the untreated cells (C). Panel E shows 
the results of the Rho GTPase activation assay carried out on the D3 73 cells cultured without any serum (a), treated for 5 min with a 
medium containing 5% serum (b), and with neurotensin at 10-8 M for 5 (c) and 10 (d) min. 
 
Published in: Neuropathology and Applied Neurobiology (2006), vol.32, iss.6, pp. 575-584 
Status: Postprint (Author’s version) 
Neurotensin decreases the motility of U373 glioblastoma cells cultured on plastic in a serum-free medium 
We used an in vitro wound-healing assay to determine the effect of neurotensin on U373 cell motility. Cell-free 
zones were created in confluent U373 monolayers by scratching off cells with a pipette tip. Each cell-free zone 
(see the black rectangle in Figure 4A) was approximately 250-300 µm wide and several millimetres long. Time-
lapse microscopy was used to analyse the recolonization rate of the cell-free zone (Figure 4B). Whereas 
neurotensin had no effect on U373 tumour cell motility when these cells were cultured in the presence of 5% 
foetal bovine serum (Figure 4C), it significantly reduced the motility level at 0.1 and 10 nM (P<0.001 at 40 h 
post treatment) when the cells were cultured in a serum-free medium (Figure 4D). At 1 µM the neurotensin-
induced decrease in U3 73 tumour cell motility was much less accentuated (P<0.05 at 40 h post treatment; 
Figure 4D). 
Neurotensin decreases the motility of U373 glioblastoma cells cultured on plastic, but increases it when U373 
cells are cultured on laminin 
Computer-assisted phase-contrast microscopy (quantitative videomicroscopy) enabled the neurotensin-induced 
effects on the motility levels of the U373 glioblastoma cells to be quantitatively determined. These motility 
levels refer to the largest linear distance travelled by individual U3 73 cells per hour, and were obtained by 
computing the MRDO variable expressed in µm/h. Figure 5A shows that 0.1 and 10nM neurotensin significantly 
decreased the levels of motility of the whole U373 cell population analysed ('100%') as well as of the 25% most 
motile U373 cells (determined as shown in Figure 1D) when the cells were cultured on plastic. In sharp contrast, 
neurotensin increased the levels of motility of U373 glioblastoma cells cultured on laminin, with a more 
pronounced effect on the 25% most motile cells than on the U373 cell population as a whole (Figure 5B). Higher 
doses (that is, 1 µM or higher) of neurotensin were not assayed in this cell motility assay because the wound-
healing experiment had previously shown that pharmacological doses of neurotensin are no more effective on 
U373 cell motility (Figure 4). 
 
Figure 4: Neurotensin-mediated effects on scratch wound colonization by D373 cells. Illustration of (A) a scratch 
wound carried out by means of a pipette tip and (B) recolonized over 40 h by U373 cells cultured in a medium supplemented with 5% foetal 
bovine serum. The percentages of surface area filled by the cells are quantified in the black rectangles shown in panels A and B and in 
function of the time line depicted on the x axes of panels C and D. These panels show the recolonization curves measured in the case of the 
cells cultured in a medium supplemented with 5% foetal bovine serum (C), and in the absence of serum (D). The data (expressed in 
percentage) are displayed as the means ± SE (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001). Black squares = control; open squares = neurotensin at 
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Figure 5: Neurotensin-mediated effects on the motility of the U373 cells quantified by means of computer-
assisted videomicroscopy Panels A and B show the variation (%) of the MRDO (Maximum Relative Distance 
from the point of Origin) values induced by neurotensin in the case of U373 cells grown on a plastic (A) or a 
laminin-coated support (B). The MRDO mean of untreated cells is arbitrarily set at 0%. The results are pooled from at least three 
independent experiments over a tracking period of 12 h and are shown relative to both the whole cell population analysed (100%) and to the 
2 5% most motile one (determined as shown in Figure 1D). The variations induced by neurotensin at 10-10 and 10-8 M are expressed in terms 
of the means ± SE (ns, not significant; *P < 0.05, **P < 0.01, ***P< 0.001). 
 
Discussion 
Neurotensin is a tridecapeptide originally isolated from bovine hypothalamus and is located mainly in the CNS 
and the endocrinal cells (N cells) of the jejunal and ileal mucosa [27]. It is synthesized in the neurones in the 
whole of the brain [35]. In the CNS, neurotensin plays the role of a neurotransmitter and also acts as a 
neuromodulator of dopamine transmission and anterior pituitary hormone secretion [26]. It also has potent 
hypothermic and analgesic effects in the brain [26]. However, as emphasized by Reubi [26], several lines of 
evidence also suggest that neurotensin plays a role in cancer. Several types of cancers, that is, small cell lung 
cancers, neuroblastomas, medulloblastomas, pancreatic cancers, colon cancers, meningiomas, Ewing's sarcomas, 
medullary thyroid carcinomas and astrocytomas, express NTRs [9,26]. As also argued by Reubi [26], an 
additional argument in favour of a role for neurotensin in cancer is the stimulation that this peptide exerts on the 
in vitro proliferation of tumour cell lines of various origins including the pancreas, the prostate and the lungs, 
and also of astrocytic tumour cell lines, as we have previously showed [10]. As is pointed out in the 
Introduction, the hallmark of malignant glioma development is their diffuse invasion of the brain parenchyma. 
This diffuse invasion is related to a myriad of individual tumour astrocytes migrating from the primary tumour 
site through the brain (possibly over long distances) [2]. Several studies have already pointed to a direct role 
played by neurotensin with respect to the migratory characteristics of a large set of cell types, including normal 
and tumour cells. For example, neurotensin modulates the locomotion of the neutrophils [37], the lymphocytes 
[38] and the macrophages [39] that form part of the immune system, and also of microglia in the CNS [40]. 
Neurotensin stimulates intestinal wound healing [41] and angiogenesis [42]. It also modulates the migration 
features of cancer cells such as circulating malignant Sezary cells [43]. The data from the present study clearly 
indicate that whereas neurotensin decreases the levels of motility of human U373 glioblastoma cells cultured on 
plastic in a serum-free medium, no such effects are observed in culture media supplemented with 5% foetal 
bovine serum (which may contain either some traces of neurotensin or a number of factors activating the same 
signalling pathways as neurotensin). Moreover, while the neurotensin-induced decrease in U373 cell motility on 
plastic in a serum-free medium was observed at 0.1 and 10 nM, this effect was abolished at a higher dose (1 
µM). We observed very similar effects on the Hs683 model (data not shown), another aggressive human glioma 
of oligodendroglial origins [23,24]. Most neuropeptides binding to GPCRs at physiological doses markedly 
modify the levels of expression and/or activity of a number of protein kinases C (PKCs) that play pivotal roles in 
the control of neuropeptide-mediated effects on cell proliferation and/or migration [8,18]. The lack of response 
to neuropeptides at pharmacological doses (in the micro-molar range) may be related to a desensitization process 
of the PKCs, as it has already been observed for gastrin in several cell systems [5,8,44]. Indeed, we observed 
higher gastrin-induced modifications at tumour astrocyte cell proliferation [5] and migration [8] levels at a 
concentration of 10 nM rather than of 1 µM. A similar observation has been reported by Kimura et al. [44], who 
noted that whereas micromolar concentrations of gastrin-cholecystokinin-related peptides inhibit PKC activity in 
acini, physiological concentrations of these peptides activate PKC-dependent signals. 
Published in: Neuropathology and Applied Neurobiology (2006), vol.32, iss.6, pp. 575-584 
Status: Postprint (Author’s version) 
Neurotensin signals its biological effects through NTR1, NTR2 and NTR3, the three different receptors 
identified to date which are widely expressed throughout the adult rat brain [29-31]. The NTR1 signalling 
pathway is well documented and includes Ca2+ release from inositol1,4,5-triphosphate (IP3)-sensitive channels, the 
activation of mitogen-activated protein Rinases (MAPKs) via PKC, and the activation of AP-1 [26,27]. In 
contrast, the signalling pathway that governs the interaction between neurotensin and NTR2 is a matter of 
controversy [26]. NTR2 seems to be involved in the analgesic effect of the peptide [26,40]. The activation of 
NTR3 by neurotensin leads to the phosphorylation of both extracellular signal-regulating kinases (ERK) 1/2 
MAPK and Akt [40]. In addition, Martin etal. [45] provide biochemical evidence for the heterodimerization of 
NTR1 and NTR3 in the human HT-29 colon cancer cell line. NTR3 is the only NTR present in all the cancer 
cells on which neurotensin has a proliferative effect [40]. It is the only known receptor expressed in human 
C13NJ microglial cells, and the effect of neurotensin on the migration of these cells is preceded by a profound 
modification of the F-actin cytoskeleton, and particularly by the rapid formation of numerous cell filopodia [40], 
a feature also observed here in U373 glioblastoma cells treated with neurotensin. In the case of other cell types 
(such as T lymphocytes and leukaemic Jurkat cells) it seems that only NTR1 is responsible for cell migration 
[42]. The present study shows that human U373 glioblastoma cells express NTR1, NTR2 and NTR3 at least at 
mRNA level, an expression pattern that we also evidenced in Hs683 glioma cells (data not shown). We cannot 
argue at present in favour of one or another specific receptor as the mediator of the neurotensin-induced effects 
on U373 cells. We are now developing an siRNA approach targeting each of these three NTRs to further 
characterize which one(s) is (are) involved in the neurotensin-induced effects on U373 cell motility. 
An intriguing finding of this study is the opposite effects of neurotensin on the motility of U373 cells cultured on 
plastic or laminin. These differences possibly reflect the engagement of different integrins depending of the 
culture support. With respect to this hypothesis, Ding et al. [46] reported that the physiological platelet-derived 
growth factor (PDGF) stimulation of U-87 MG glioblastoma cells largely promotes αvβ3-mediated motility on 
vitronectin in contrast to the much lower migration rates observed on collagen or laminin (which engage 
different integrins). On the other hand, the levels of eosinophil chemotaxis induced by the platelet-activating 
factor were enhanced on laminin but not on vitronectin [47]. These data illustrate the profound impact of the 
cell-matrix interactions through the engagement of different integrins on the regulation of cell migration by 
soluble factors. 
The present study reveals that the neurotensin-induced effects observed in U373 cell motility are paralleled by 
profound modifications to the organization of the U373 actin cytoskeleton that could at least be partly explained 
by pronounced modifications at small GTPases activation level. Indeed, we observed that neurotensin is able to 
activate Racl and Cdc42 in U373 cells. These data agree with those reported by Zao et al. on human colonic 
epithelial cells overexpressing NTR1 [48]. The activation of Racl and Cdc42, which are known to stimulate the 
formation of actin-based membrane protrusions [19], might thus explain the morphological changes observed in 
the U373 cells treated with neurotensin. The accumulation of fibrillar actin to form strong adhesion plaques at 
the tips of the filopodial protrusions might also explain the restricted motility of U373 cells induced by 
neurotensin. 
In conclusion, our data strongly suggest that neurotensin is a neuropeptide capable of modulating tumour 
astrocyte migration into the brain parenchyma by acting on the actin cytoskeleton and its regulators at least. 
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